TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29449958

Group type: EXPERIMENTAL
Intervention: JOOL Health application
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: JOOL Health application and Fitbit activity tracker and wireless-enabled scale
Number of subjects: 105

Group type: COMPARATOR
Intervention: Information on prediabetes and evidence-based strategies to decrease progression to T2DM (comparison group)
Number of subjects: 105
Study: 29450008

Group type: EXPERIMENTAL
Intervention: Hot-seat role
Number of subjects: 37

Group type: COMPARATOR
Intervention: Observer role
Number of subjects: 37
Study: 29450194

Group type: EXPERIMENTAL
Intervention: NIRS group (simultaneous cTOI and pTOI monitoring)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (routine monitoring and treatment)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: NIRS group (echocardiography performed due to NIRS measurements)
Number of subjects: 49
Study: 29450722

Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy
Number of subjects: 392

Group type: COMPARATOR
Intervention: Targeted drug therapy
Number of subjects: 392

Group type: COMPARATOR
Intervention: Balloon pulmonary angioplasty
Number of subjects: 392
Study: 29450753

Group type: EXPERIMENTAL
Intervention: Annual mammography
Number of subjects: 9835

Group type: EXPERIMENTAL
Intervention: Breast MRI
Number of subjects: 9835

Group type: COMPARATOR
Intervention: Lack of imaging
Number of subjects: 9835

Group type: EXPERIMENTAL
Intervention: Receipt of breast MRI
Number of subjects: 9835
Study: 29451431

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interferential current
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aussie current
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29451447

Group type: EXPERIMENTAL
Intervention: Peripheral nerve grafts implanted into the substantia nigra during DBS surgery
Number of subjects: 8
Study: 29451701

Group type: EXPERIMENTAL
Intervention: Pasireotide (600 μg twice daily), Everolimus (10 mg/day), SIRT (SIR-Spheres dose on days 9 and 37)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pasireotide, Everolimus, and SIRT
Number of subjects: 13
Study: 29451706

Group type: EXPERIMENTAL
Intervention: IDegAsp (insulin degludec and insulin aspart) twice daily
Number of subjects: 1808

Group type: COMPARATOR
Intervention: BIAsp 30 (premixed insulin) twice daily
Number of subjects: 1808

Group type: COMPARATOR
Intervention: IDeg + IAsp (insulin degludec once daily + insulin aspart)
Number of subjects: 1808
Study: 29451806

Group type: EXPERIMENTAL
Intervention: High-wattage e-cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29452121

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg b.i.d. initially, escalated to 10 mg b.i.d. for nonresponders)
Number of subjects: 12
Study: 29452135

Group type: EXPERIMENTAL
Intervention: Supervised-exercise training (ET) interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions including supervised-ET
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance ET at vigorous or moderate-to-vigorous intensities, with a volume ≥60 min/session and a frequency ≥3 sessions/week
Number of subjects: 0
Study: 29452209

Group type: EXPERIMENTAL
Intervention: Prolactin (PRL) treatment in FFA-induced HepG2 cells
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Prolactin receptor (PRLR) overexpression in FFA-induced HepG2 cells
Number of subjects: 456

Group type: COMPARATOR
Intervention: Silencing of PRLR
Number of subjects: 456

Group type: COMPARATOR
Intervention: Overexpression of CD36
Number of subjects: 456

Group type: COMPARATOR
Intervention: Comparison of serum PRL levels between NAFLD and non-NAFLD individuals
Number of subjects: 456

Group type: COMPARATOR
Intervention: Comparison of PRL levels in patients with severe vs mild-to-moderate hepatic steatosis
Number of subjects: 456
Study: 29452351

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) within 60 to 180 minutes from first medical contact
Number of subjects: 12675

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 12675
Study: 29452402

Group type: EXPERIMENTAL
Intervention: Mitotane monotherapy
Number of subjects: 127
Study: 29452421

Group type: EXPERIMENTAL
Intervention: LC-MS/MS measurement of cortisol at 30 minutes after intravenous administration of 250 µg tetracosactide acetate.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: LC-MS/MS measurement of cortisol at 60 minutes after intravenous administration of 250 µg tetracosactine acetate.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: LC-MS/MS measurement of 17-OHP at 30 minutes after intravenous administration of 250 µg tetracosactine acetate.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: LC-MS/MS measurement of 17-OHP at 60 minutes after intravenous administration of 250 µg tetracosactine acetate.
Number of subjects: 232

Group type: COMPARATOR
Intervention: Comparison of LC-MS/MS with routine immunoassays (Immulite and Roche platforms).
Number of subjects: 232
Study: 29452808

Group type: EXPERIMENTAL
Intervention: Norepinephrine administration during early resuscitation
Number of subjects: 38
Study: 29452956

Group type: EXPERIMENTAL
Intervention: Face-to-face interaction
Number of subjects: 743

Group type: COMPARATOR
Intervention: EMR review
Number of subjects: 743
Study: 29452941

Group type: EXPERIMENTAL
Intervention: High-HDI countries
Number of subjects: 12539

Group type: EXPERIMENTAL
Intervention: Middle-HDI countries
Number of subjects: 12539

Group type: EXPERIMENTAL
Intervention: Low-HDI countries
Number of subjects: 12539

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 12539

Group type: EXPERIMENTAL
Intervention: Patients with SSI and resistant infections
Number of subjects: 12539

Group type: EXPERIMENTAL
Intervention: High-HDI countries resistant infections
Number of subjects: 12539

Group type: EXPERIMENTAL
Intervention: Middle-HDI countries resistant infections
Number of subjects: 12539

Group type: EXPERIMENTAL
Intervention: Low-HDI countries resistant infections
Number of subjects: 12539

Group type: EXPERIMENTAL
Intervention: Risk factor adjustment
Number of subjects: 12539
Study: 29453190

Group type: EXPERIMENTAL
Intervention: Redesigned monthly emails with content operationalizing anticipated regret, material incentive (behavior), and problem solving.
Number of subjects: 5576

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 5576
Study: 29453305

Group type: EXPERIMENTAL
Intervention: Reduced dose NOACs (1289 patients)
Number of subjects: 7925

Group type: COMPARATOR
Intervention: Standard dose NOACs (6636 patients)
Number of subjects: 7925
Study: 29454306

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d until progression or intolerance
Number of subjects: 134
Study: 29454321

Group type: EXPERIMENTAL
Intervention: Temsirolimus, 25 mg IV weekly until progression, unacceptable toxicities or withdrawal
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 54
Study: 29454364

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine A at 2.5 mg/kg/day
Number of subjects: 5
Study: 29454380

Group type: EXPERIMENTAL
Intervention: Ministernotomy ("J" shaped upper hemisternotomy toward right 4th intercostal space)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 100
Study: 29454592

Group type: EXPERIMENTAL
Intervention: Telavancin (TLV)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Vancomycin (VAN)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Telavancin (TLV) for monomicrobial SA-HABP
Number of subjects: 433
Study: 29454660

Group type: EXPERIMENTAL
Intervention: CATT treatment
Number of subjects: 1061
Study: 29454762

Group type: EXPERIMENTAL
Intervention: Right Ventricular Dysfunction (RVD)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Normal RV function
Number of subjects: 1116
Study: 29454767

Group type: EXPERIMENTAL
Intervention: Automated MBF pixel maps
Number of subjects: 97
Study: 29454776

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance myocardial feature tracking (CMR-FT)
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: CMR-FT
Number of subjects: 1235
Study: 29455032

Group type: EXPERIMENTAL
Intervention: Sevoflurane administered with an expired fraction target of 2% during short-term procedural sedation.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (non-burn patients).
Number of subjects: 24
Study: 29455308

Group type: EXPERIMENTAL
Intervention: Colloids (6% hydroxyethyl starch HES 130/0.4)
Number of subjects: 4545

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch HES 130/0.4
Number of subjects: 4545

Group type: COMPARATOR
Intervention: Crystalloids only
Number of subjects: 4545
Study: 29456073

Group type: EXPERIMENTAL
Intervention: Isocaloric low-carbohydrate diet with increased protein content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liver transcriptomic analysis
Number of subjects: 0
Study: 29456445

Group type: EXPERIMENTAL
Intervention: Pressure Pain Threshold Scale (PPTS)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Digital pressure sensor and algometer
Number of subjects: 84
Study: 29456529

Group type: EXPERIMENTAL
Intervention: High-dose immunosuppressive therapy combined with autologous CD34+ hematopoietic stem cell transplantation (AHSCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29456629

Group type: EXPERIMENTAL
Intervention: Acute vitamin C infusion
Number of subjects: 31
Study: 29457537

Group type: EXPERIMENTAL
Intervention: Spatialization feature in wireless microphone systems
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diotic stimuli
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Artificial spatial hearing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Natural spatial hearing
Number of subjects: 40
Study: 29457758

Group type: EXPERIMENTAL
Intervention: Estradiol transdermal patch (0.3 mg/day) during artificial cycle
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate suppression and estradiol patches
Number of subjects: 6

Group type: COMPARATOR
Intervention: Natural cycle
Number of subjects: 6
Study: 29458189

Group type: EXPERIMENTAL
Intervention: Conventional monoexponential tensor model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual compartment tensor model
Number of subjects: 0
Study: 29458314

Group type: EXPERIMENTAL
Intervention: Blended-learning programme regarding professional ethics (8 months)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (public exposition of a clinical case about professional ethics for 8 months)
Number of subjects: 129
Study: 29458388

Group type: EXPERIMENTAL
Intervention: 1928zT2 T cells
Number of subjects: 3
Study: 29458518

Group type: EXPERIMENTAL
Intervention: Perceived Stress in boys
Number of subjects: 139

Group type: COMPARATOR
Intervention: Moderate-to-vigorous physical activity (MVPA) in girls
Number of subjects: 139

Group type: COMPARATOR
Intervention: Daily stress in girls
Number of subjects: 139

Group type: COMPARATOR
Intervention: Perceived stress in girls
Number of subjects: 139

Group type: COMPARATOR
Intervention: Coping strategies in girls
Number of subjects: 139
Study: 29458699

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 2 weeks nightly
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 36
Study: 29458705

Group type: EXPERIMENTAL
Intervention: SCISD (Structured Clinical Interview for DSM-5 Sleep Disorders)
Number of subjects: 106
Study: 29459355

Group type: EXPERIMENTAL
Intervention: Eligibility criteria requiring mobile phone ownership and an unlimited text messaging plan
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Mobile phone inclusion criteria
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Comparison of employed vs unemployed individuals
Number of subjects: 1003
Study: 29459395

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis on the Stroke Emergency Mobile (STEMO)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Intravenous thrombolysis through conventional in-hospital care (CC)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Both STEMO and CC
Number of subjects: 264
Study: 29459474

Group type: EXPERIMENTAL
Intervention: Myocardial Scar
Number of subjects: 0
Study: 29459949

Group type: EXPERIMENTAL
Intervention: Nilotinib during consolidation phase, followed by treatment discontinuation for TFR.
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Reinitiated nilotinib therapy after loss of MMR or confirmed loss of MR4 during TFR.
Number of subjects: 163
Study: 29460080

Group type: EXPERIMENTAL
Intervention: Obese women with a history of GDM
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Non-obese women
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Non-obese women before pregnancy
Number of subjects: 333
Study: 29460398

Group type: EXPERIMENTAL
Intervention: aCGH with classical centralization-normalization steps
Number of subjects: 66

Group type: COMPARATOR
Intervention: FISH
Number of subjects: 66
Study: 29460668

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone in preventing opioid dependence relapse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tools to ascertain participants' sense of personal control in joining research
Number of subjects: 0
Study: 29460699

Group type: EXPERIMENTAL
Intervention: SRI(4) responders
Number of subjects: 736
Study: 29460815

Group type: EXPERIMENTAL
Intervention: Short Nutritional Assessment Questionnaire (SNAQ)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Phase angle measured with bio-impedance
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Phase angle
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Malnutrition (SNAQ and phase angle)
Number of subjects: 299
Study: 29461687

Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg and grazoprevir 100 mg for 12 weeks without ribavirin
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg and grazoprevir 100 mg for 16 weeks plus ribavirin
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg and grazoprevir 100 mg for 12 or 16 weeks
Number of subjects: 155
Study: 29461859

Group type: EXPERIMENTAL
Intervention: Five-Grass Pollen Tablet Sublingual Immunotherapy
Number of subjects: 0
Study: 29461919

Group type: EXPERIMENTAL
Intervention: HZ/su (50 µg varicella-zoster virus glycoprotein E [gE] and AS01)
Number of subjects: 70
Study: 29461925

Group type: EXPERIMENTAL
Intervention: Individuals with comorbid AUD and PTSD
Number of subjects: 113

Group type: COMPARATOR
Intervention: Individuals with AUD only
Number of subjects: 113
Study: 29462123

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for ≥2 years or until disease progression or unacceptable toxicity
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 26
Study: 29462193

Group type: EXPERIMENTAL
Intervention: Lower TLDF (38.0°C)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard TLDF (39.0°C)
Number of subjects: 45
Study: 29462229

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXE Q2W)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Etanercept twice weekly
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Ixekizumab (after 2 weeks)
Number of subjects: 156
Study: 29462629

Group type: EXPERIMENTAL
Intervention: Multiple targeted cervical biopsies based on screening cytology, human papillomavirus testing, and colposcopic impression
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Multiple biopsies
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Initial colposcopy with multiple biopsies
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Follow-up cytology or histology data
Number of subjects: 690
Study: 29463275

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) initiated within 24 hours of PICU admission
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Late parenteral nutrition (PN) withheld for one week in PICU
Number of subjects: 1148
Study: 29463285

Group type: EXPERIMENTAL
Intervention: Muscle training (specific details not provided)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 15
Study: 29463421

Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study: 29463490

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and medication review by a clinical pharmacist, 2 to 5 times over 7 months after standard follow-up at the cardiology clinic.
Number of subjects: 417

Group type: COMPARATOR
Intervention: Standard follow-up at the cardiology clinic.
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and medication review by a clinical pharmacist.
Number of subjects: 417
Study: 29463493

Group type: EXPERIMENTAL
Intervention: Impulsive compression foot pump
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard postoperative routines (short-stretch bandaging)
Number of subjects: 100
Study: 29463520

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Statin therapy initiated during the study (in patients who were not on statins at baseline)
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Baseline statin users
Number of subjects: 1476
Study: 29463526

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study: 29463550

Group type: EXPERIMENTAL
Intervention: Glasdegib in combination with standard chemotherapy
Number of subjects: 0
Study: 29463563

Group type: EXPERIMENTAL
Intervention: IL-15 superagonist complex ALT-803
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29463621

Group type: EXPERIMENTAL
Intervention: ERGO+NIV (Non-invasive ventilation)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: ERGO+RMT (Respiratory muscle training)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cycling exercise training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cycling exercise training alone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: NIV and exercise training
Number of subjects: 53
Study: 29464110

Group type: EXPERIMENTAL
Intervention: TAK-228 QD (3 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: TAK-228 3 days/week plus paclitaxel 80 mg/m
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: TAK-228 QW (30 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: TAK-228 (milled capsules)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall exposure (area under the plasma concentration-time curve)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: TAK-228
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Study drugs
Number of subjects: 61
Study: 29464420

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Propofol-opioid (PO)
Number of subjects: 297
Study: 29464830

Group type: EXPERIMENTAL
Intervention: DASH diet (highest tertile of DASH score)
Number of subjects: 632
Study: 29465308

Group type: EXPERIMENTAL
Intervention: Debulking treatment with bendamustine followed by induction and maintenance treatment with anti-CD20 antibody (obinutuzumab or ofatumumab) and a targeted oral agent (ibrutinib, idelalisib, or venetoclax).
Number of subjects: 60
Study: 29465480

Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine
Number of subjects: 5902

Group type: EXPERIMENTAL
Intervention: Antipyretic use
Number of subjects: 5902

Group type: COMPARATOR
Intervention: First dose of trivalent influenza vaccine
Number of subjects: 5902

Group type: COMPARATOR
Intervention: Second dose of trivalent influenza vaccine
Number of subjects: 5902
Study: 29466156

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 55
Study: 29466429

Group type: EXPERIMENTAL
Intervention: Green tea extract capsules standardized to 150 mg epigallocatechin-gallate (EGCG) twice a day for 5 days
Number of subjects: 84
Study: 29466925

Group type: EXPERIMENTAL
Intervention: Peripheral VA-ECMO with direct biventricular decompression (trans-apical LV venting cannula and right ventricular decompression cannula)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral VA-ECMO
Number of subjects: 0
Study: 29467017

Group type: EXPERIMENTAL
Intervention: Ulinastatin 400,000 IU three times a day for 10 days
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo and usual care
Number of subjects: 348
Study: 29467098

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine provided at no cost
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir diphosphate disoproxil fumarate plus emtricitabine
Number of subjects: 450
Study: 29467121

Group type: EXPERIMENTAL
Intervention: Wearable device-generated data monitoring (Fitbit Charge HR or Fitbit Charge 2) for heart rate, physical activity, and sleep in patients with thyrotoxicosis.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (10 control subjects)
Number of subjects: 40
Study: 29467321

Group type: EXPERIMENTAL
Intervention: MK-8353 (400 mg twice daily)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: MK-8353 (100-800 mg dose cohorts)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: MK-8353 (various doses)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: MK-8353
Number of subjects: 74
Study: 29467544

Group type: EXPERIMENTAL
Intervention: Capnoperitoneum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mechanical ventilation without capnoperitoneum
Number of subjects: 20
Study: 29467758

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment
Number of subjects: 23
Study: 29468069

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation (≥ 1500 mL)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Adrenergic agents
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Total SOFA score on admission
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Management outside of ICUs
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 454